BC Week In Review | Feb 9, 2015
Clinical News

Azedra: Phase II resumed

Progenics restarted dosing patients in an open-label, pivotal U.S. Phase II trial evaluating 2 doses of 500 mCi or 8 mCi/kg Azedra given about 3 months apart in about 75 patients ages >=12. In late...
BC Week In Review | Feb 3, 2014
Clinical News

99mTc-MIP-1404: Interim Phase II data

Interim data from 54 evaluable high-risk men with confirmed adenocarcinoma of the prostate who were scheduled for radical prostatectomy with extended pelvic lymph node dissection in an open-label, international Phase II trial showed that a...
BC Week In Review | Dec 9, 2013
Clinical News

Azedra: Phase IIb start

Progenics said it plans to resume an open-label, U.S., pivotal Phase IIb trial evaluating 2 doses of 500 mCi or 8 mCi/kg Azedra given about 3 months apart in about 75 patients. The company hopes...
BC Week In Review | Sep 30, 2013
Company News

Progenics, ITM Isotope Technologies Munich AG deal

Progenics granted ITM exclusive rights to manufacture and market Onalta edotreotide to treat cancer. ITM received worldwide rights except for Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia,...
BC Week In Review | Jul 15, 2013
Clinical News

99mTc-MIP-1404: Phase I data

An open-label, U.S. Phase I trial in about 24 prostate cancer patients scheduled for prostatectomy and/or extended pelvic lymph node dissection showed that a single IV dose of 99mTc-MIP-1404 was well distributed and ready for...
BC Week In Review | Jan 28, 2013
Company News

Molecular Insight, Progenics deal

Progenics acquired Molecular Insight in a deal worth up to $105.9 million. Molecular Insight shareholders received 4.6 million Progenics shares valued at $12.9 million based on Progenics' close of $2.83 on Jan. 18, before the...
BC Week In Review | Oct 1, 2012
Clinical News

99mTc-MIP-1404: Phase II started

Molecular Insight began an open-label, international Phase II trial to evaluate a single IV dose of 99mTc-MIP-1404 followed by SPECT/CT scans 3-6 hours after injection in up to 120 high-risk prostate cancer patients scheduled for...
BC Week In Review | Apr 9, 2012
Company News

Knome management update

Knome Inc. , Cambridge, Mass.   Business: Genomics   Hired: Charles Abdalian as CFO, formerly SVP of finance and CFO of Molecular Insight Pharmaceuticals Inc. ; Adam Rosenberg as SVP and head of corporate development; Jay...
BC Week In Review | May 23, 2011
Financial News

Molecular Insight financial update

Molecular Insight deregistered from the Securities Exchange Commission after filing for Chapter 11 bankruptcy in December (see BioCentury, Dec. 20, 2010). Molecular Insight Pharmaceuticals Inc. , Cambridge, Mass.   Business: Diagnostic, Cancer   Date announced: 5/13/11...
BC Week In Review | May 16, 2011
Company News

Molecular Insight diagnostic news

Molecular Insight said the U.S. Bankruptcy Court for the District of Massachusetts approved the biotech's amended reorganization plan as part of its Chapter 11 proceedings initiated last year. The plan will reduce Molecular Insight's outstanding...
Items per page:
1 - 10 of 125
BC Week In Review | Feb 9, 2015
Clinical News

Azedra: Phase II resumed

Progenics restarted dosing patients in an open-label, pivotal U.S. Phase II trial evaluating 2 doses of 500 mCi or 8 mCi/kg Azedra given about 3 months apart in about 75 patients ages >=12. In late...
BC Week In Review | Feb 3, 2014
Clinical News

99mTc-MIP-1404: Interim Phase II data

Interim data from 54 evaluable high-risk men with confirmed adenocarcinoma of the prostate who were scheduled for radical prostatectomy with extended pelvic lymph node dissection in an open-label, international Phase II trial showed that a...
BC Week In Review | Dec 9, 2013
Clinical News

Azedra: Phase IIb start

Progenics said it plans to resume an open-label, U.S., pivotal Phase IIb trial evaluating 2 doses of 500 mCi or 8 mCi/kg Azedra given about 3 months apart in about 75 patients. The company hopes...
BC Week In Review | Sep 30, 2013
Company News

Progenics, ITM Isotope Technologies Munich AG deal

Progenics granted ITM exclusive rights to manufacture and market Onalta edotreotide to treat cancer. ITM received worldwide rights except for Albania, Algeria, Bahrain, Bulgaria, Cyprus, Greece, Iran, Iraq, Kuwait, Lebanon, Oman, Qatar, Romania, Saudi Arabia,...
BC Week In Review | Jul 15, 2013
Clinical News

99mTc-MIP-1404: Phase I data

An open-label, U.S. Phase I trial in about 24 prostate cancer patients scheduled for prostatectomy and/or extended pelvic lymph node dissection showed that a single IV dose of 99mTc-MIP-1404 was well distributed and ready for...
BC Week In Review | Jan 28, 2013
Company News

Molecular Insight, Progenics deal

Progenics acquired Molecular Insight in a deal worth up to $105.9 million. Molecular Insight shareholders received 4.6 million Progenics shares valued at $12.9 million based on Progenics' close of $2.83 on Jan. 18, before the...
BC Week In Review | Oct 1, 2012
Clinical News

99mTc-MIP-1404: Phase II started

Molecular Insight began an open-label, international Phase II trial to evaluate a single IV dose of 99mTc-MIP-1404 followed by SPECT/CT scans 3-6 hours after injection in up to 120 high-risk prostate cancer patients scheduled for...
BC Week In Review | Apr 9, 2012
Company News

Knome management update

Knome Inc. , Cambridge, Mass.   Business: Genomics   Hired: Charles Abdalian as CFO, formerly SVP of finance and CFO of Molecular Insight Pharmaceuticals Inc. ; Adam Rosenberg as SVP and head of corporate development; Jay...
BC Week In Review | May 23, 2011
Financial News

Molecular Insight financial update

Molecular Insight deregistered from the Securities Exchange Commission after filing for Chapter 11 bankruptcy in December (see BioCentury, Dec. 20, 2010). Molecular Insight Pharmaceuticals Inc. , Cambridge, Mass.   Business: Diagnostic, Cancer   Date announced: 5/13/11...
BC Week In Review | May 16, 2011
Company News

Molecular Insight diagnostic news

Molecular Insight said the U.S. Bankruptcy Court for the District of Massachusetts approved the biotech's amended reorganization plan as part of its Chapter 11 proceedings initiated last year. The plan will reduce Molecular Insight's outstanding...
Items per page:
1 - 10 of 125